Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Oktober 2016 01:05 ET | Quelle: Ablynx

ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS

AbbVie has decided at this time not to exercise its right to opt-in and license vobarilizumab in RA Additional analysis of the Phase IIb RA studies of vobarilizumab further demonstrate its...
12. Oktober 2016 01:04 ET | Quelle: Ablynx

ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.

GHENT, Belgium, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced a second extension of its research collaboration with a subsidiary of Merck & Co.,...
11. Oktober 2016 01:05 ET | Quelle: Ablynx

FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION GHENT, Belgium, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2...
10. Oktober 2016 01:15 ET | Quelle: Ablynx

ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP

To evaluate the long-term safety and efficacy of caplacizumab To evaluate the safety and efficacy of repeated treatment with caplacizumab To characterise the severity and long term impact...
29. September 2016 01:05 ET | Quelle: Ablynx

ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP

GHENT, Belgium, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announced that it will today present additional data from post-hoc analyses of the Phase II TITAN study...
15. September 2016 01:07 ET | Quelle: Ablynx

ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.

REGULATED INFORMATION GHENT, Belgium, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
06. September 2016 01:19 ET | Quelle: Ablynx

Ablynx Receives Transparency Notification From GAM Holding AG, GAM International Management Limited and Taube Hodson Stonex Partners LLP

GHENT, Belgium, Sept. 6, 2016 (GLOBE NEWSWIRE) -- REGULATED INFORMATION Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
25. August 2016 01:10 ET | Quelle: Ablynx

ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE

REGULATED INFORMATION Very important clinical pipeline developments and a successful financing Conference call and webcast today at 4pm CET/10am ET GHENT, Belgium, Aug. 25, 2016 (GLOBE...
17. August 2016 01:09 ET | Quelle: Ablynx

ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016

GHENT, Belgium, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2016 half year financial results and year-to-date business update on Thursday 25 August...
12. August 2016 01:06 ET | Quelle: Ablynx

ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.

REGULATED INFORMATION GHENT, Belgium, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2...

Nächste Seite